Company
About us
Acticor Team
Board of Directors
investors & Partners
Prizes & Awards
Our Product
Our product: Glenzocimab
GPVI / GLENZOCIMAB in brief
in acute ischemic stroke
⮑ Positive results actimis study
in other indications
Pipeline
About stroke
Key figures
What is a stroke?
Media
Press Releases
Publications
Media Coverage
Events
Investors
Welcome
Corporate Presentation
Share Overview
Shareholders' Meeting
Regulated Information
Financial Agenda
COntact
Investors
Media Coverage
November 9, 2018
Les Échos : la start-up Acticor, qui développe un traitement contre les AVC, a bouclé une levée de fonds en série B de 15,3 millions d’euros